Visceral and subcutaneous fat in patients treated with olanzapine

• Verfasst von: Gilles, Maria [VerfasserIn]
• Verfasst von: Hentschel, Frank [VerfasserIn]
• Verfasst von: Paslakis, Georgios [VerfasserIn]
• Verfasst von: Glahn, Eva Valerie [VerfasserIn]
• Verfasst von: Lederbogen, Florian [VerfasserIn]
• Verfasst von: Deuschle, Michael [VerfasserIn]
• Titel: Visceral and subcutaneous fat in patients treated with olanzapine
• Titelzusatz: a case series
• Verf.angabe: Maria Gilles, Frank Hentschel, Georgios Paslakis, Valerie Glahn, Florian Lederbogen, Michael Deuschle
• Jahr: 2010
• Umfang: 2 S.
• Fussnoten: Gesehen am 15.10.2020
• Titel Quelle: Enthalten in: Clinical neuropharmacology
• Ort Quelle: Philadelphia, Pa. : Lippincott Williams & Wilkins, 1976
• Jahr Quelle: 2010
• Band/Heft Quelle: 33(2010), 5, Seite 248-249
• ISSN Quelle: 1537-162X
• DOI: doi:10.1097/WNF.0b013e3181f0ec33
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1735645524

Abstract

Objectives: - We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome. - Methods: - Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glucose, and lipids in an unselected population of 14 schizophrenic patients. - Results: - We found a 6-week olanzapine treatment to be related to increased body mass index and proportion of total fat at the level of the fourth vertebral body. - Conclusions: - On the basis of these findings, we conclude that weight gain after a 6-week olanzapine treatment is partly attributable to increased visceral fat and may thus contribute to metabolic syndrome.